Apellis removes Common Stock from Nasdaq listing

Apellis Pharmaceuticals, Inc. notifies removal of its Common Stock from Nasdaq Stock Market LLC via Form 25.

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. notifies removal of its Common Stock from Nasdaq Stock Market LLC via Form 25. Nasdaq certified compliance with 17 CFR 240.12d2-2 and the issuer complied with exchange rules governing voluntary withdrawal. The notice is signed on behalf of Nasdaq by Katelin Rowe, CDO Analyst.

Key Figures

Commission File Number: 001-38276 Expiry/Date on top of form: March 31, 2018 Issuer telephone: 502-241-4114

3 metrics

Commission File Number 001-38276 Form 25 cover reference

Expiry/Date on top of form March 31, 2018 form header expiration date

Issuer telephone 502-241-4114 principal executive office contact

Key Terms

Form 25, 17 CFR 240.12d2-2, voluntary withdrawal of registration

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

voluntary withdrawal of registration regulatory

"the Issuer has complied with its rules of the Exchange and the requirements ... governing the voluntary withdrawal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Form 25 and what did Apellis (APLS) file?

Form 25 is a SEC notice used to remove securities from an exchange. Apellis's filing notifies the removal of its Common Stock from Nasdaq and certifies compliance with 17 CFR 240.12d2-2 procedures.

Which securities class did Apellis (APLS) withdraw from Nasdaq?

The filing explicitly lists the company's Common Stock as the class being removed. The notification addresses delisting and withdrawal procedures under the cited exchange and SEC rules.

Who executed the Nasdaq notification for the removal?

The notification was signed on behalf of Nasdaq Stock Market LLC by Katelin Rowe, identified in the filing as a CDO Analyst. The signature certifies the Exchange's compliance with the cited rule.

What regulatory citation governs the removal disclosed by Apellis (APLS)?

The filing cites 17 CFR 240.12d2-2 (including subsections (a)(1)–(a)(4) and (b)/(c)), which governs exchange delisting procedures and voluntary withdrawal of registration.

Where are Apellis's principal executive offices listed in the filing?

The filing lists Apellis's address as 6400 Westwind Way, Suite A, Crestwood, Kentucky 40014 and provides a telephone number of 502-241-4114 for the issuer's principal executive offices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 09:52 AM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38276

Issuer:	Apellis Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	6400 Westwind Way
	Suite A
	Crestwood	KENTUCKY	40014
Telephone number:					502-241-4114

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-14	By	Katelin Rowe		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.